The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

Featured Videos #1

“Treatment Limbo” – what is it and how can we avoid it?

Sponsored

Dr Adie Viljoen and Dr Mohamed Elnaggar address the challenge of “Treatment Limbo”, in dyslipidaemia management, where patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets yet remain ineligible for advanced therapies. They introduce a guideline-aligned, alternative approach that tailors treatment to baseline LDL-C and distance to goal, supporting timely intervention and helping to reduce the risk of recurrent cardiovascular events.

Click here to access prescribing information and adverse event reporting information for Praluent® (alirocumab).

MAT-XU-2504094 (v2.0) | August 2026

What to expect when you visit the National Amyloidosis Centre

An educational walkthrough video to share with your patients referred to the National Amyloidosis Centre (NAC), providing an overview of what to expect during their visit. The video describes the range of investigations that may be undertaken at the NAC, and which healthcare professionals patients may meet at their appointment.

Funding for these videos has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

The National Amyloidosis Centre: A guide for clinicians

This short video outlines the role of the NAC (National Amyloidosis Centre) in managing patients you refer to them with suspected amyloidosis. It highlighting the use of accurate diagnostic testing techniques available at the NAC, including imaging, histology and proteomics, as well as the genetic testing and counselling that provide important components of holistic care.

Funding for these videos has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

Hiding in plain sight – a case-based overview of amyloidosis

Experts from the National Amyloidosis Centre in London examine three case studies, specifically focusing upon the symptoms that first aroused suspicion, the diagnostic tests that confirmed the condition, and the treatment options available to these patients.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.

Amyloidosis: a comprehensive guide for the cardiovascular team

A guide for all members of the cardiovascular and primary care teams on what to look for, and what to do if you suspect amyloidosis: signs and symptoms, diagnostic tests and studies, and the treatment options currently available.

Funding for this video has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.